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1. INTRODUCTION 
1.1 CONTROLLED DRUG DELIVERY SYSTEM1. 
                 Therapeutic efficacy and safety of drugs, administrated by conventional methods, 
can be improved by more precise spatial and temporal placement within the body, thereby 
reducing both the size and number of doses by using controlled drug delivery system. An 
ideal controlled drug delivery system is the one which delivers the drug at predetermined rate, 
locally or systemically for a specified period of time. An ideal targeted drug delivery system 
delivers the drug only to its site of action.  
 An ideal drug delivery system should deliver the drug at a rate dictated by the needs 
of the body over the period of treatment channel the active entity solely to the site of action. 
To make it in practice various controlled and targeted drug delivery system are introduced. 
Controlled delivery of drugs, proteins and other bioactive agents can be achieved by 
incorporating them either in dissolved or dispersed form in polymers. 
In general controlled delivery attempts to, Sustain drug action at a predetermined rate 
by maintaining a relatively constant, effective drug level in the body with concomitant 
minimization of undesirable side effects associated with a saw tooth kinetic pattern. Localize 
drug action by spatial placement of a controlled release system (rate controlled) adjacent to or 
in the diseased tissue or organ. Target drug action by using carriers to deliver drugs to 
particular target cell type. 
 1.1.1 OBJECTIVES OF CONTROLLED DRUG DELIVERY SYSTEMS. 
             The chief objective of most products should be controlled delivery to reduce dosing 
frequency to an extend that once daily does is sufficient for therapeutic management though a 
uniform plasma concentration at a steady state. The major objectives include, 
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I. Predict drug release rated form and drug diffusion behaviour through polymers, thus 
avoiding excessive experimentation.  
II. Elucidate the physical mechanism of drug transport by simply comparing the release 
data mathematical models.  
III. Design new drug delivery system based on general release expressions. 
IV. Optimize the release kinetics. 
1.1.2 FACTOR INFLUENCING THE DESIGN AND PERFORMANCE 
OF CONTROLLED DRUG DELIVERY SYSTEM1. 
I. Biopharmaceutical characteristic of the drug.  
a. Molecular weight of the drug. 
b. Aqueous solubility of the drug.  
c. Apparent partition coefficient.  
d. Drug pKa and ionization physiological pH.  
e. Drug stability. 
f. Mechanism and site of absorption.  
g. Route of administration. 
II. Pharmacokinetic characteristic of the drug.  
a. Absorption rate. 
b. Elimination half life. 
c. Rate of metabolism. 
d. Dosage form index. 
III. Pharmacodynamics characteristic of the drug.  
a. Therapeutic range. 
b. Therapeutic index. 
c. Plasma–concentration–response relationship.  
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1.1.3 CLASSIFICATION OF CONTROLLED DRUG DELIVERY 
SYSTEMS1. 
1.1.3.1 ORAL CONTROLLED DRUG DELIVERY SYSTEM. 
a. Continuous release system. 
b. Dissolution controlled release system.  
c. Diffusion controlled release system. 
d. Diffusion and dissolution controlled release system. 
e. Ion exchange resin drug complexes. 
f. Slow dissolving salt and complexes. 
g. pH independent formulations. 
h. Osmotic pressure controlled systems. 
i. Hydrodynamic pressure controlled systems. 
1.1.3.2  DELAYED TRANSIT AND CONTINUOUS RELEASE SYSTEMS.  
a. Altered density system. 
b. Mucoadhesive system. 
c.  Size based systems. 
1.1.3.3 DELAYED RELEASE SYSTEM. 
a. Intestinal release system. 
b. Colonic release system. 
1.1.3.4 PARENTERAL CONTROLLED RELEASE SYSTEMS. 
a. Injectable system. 
b. Implants system. 
1.1.3.5 TRANSDERMAL DRUG DELIVERY SYSTEMS. 
1.1.3.6 OPHTHALMIC DRUG DELIVERY SYSTEMS.  
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1.1.3.7 INTRAVAGINAL AND INTRAUTERINE DRUG DELIVERY SYSTEMS. 
1.1.4 ADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEMS1,2. 
I.  Improved patient convenience and compliance due to less    frequency of    
dosing. 
II. Reduction in fluctuation in steady-state levels and therefore better control of 
disease condition and less side effects. 
III. Increased safety margin of high potency drug. 
IV. Low dose requirement because of maximum utilization of drug. 
V. Reduction in health care cost. 
1.1.5 DISADVANTAGES OF CONTROLLED DRUG DELIVERY 
SYSTEMS1,2. 
I. Decreased systemic availability.  
II. Poor in vitro- in vivo correlations.  
III. Chances of dose dumping.  
IV. Dose withdrawal is not possible. 
V. Higher cost of formulation.  
1.2 SUSTAINED RELEASE DOSAGE FORMS3,4. 
A sustained-release dosage form is defined as “any drug or dosage form modification 
that prolongs the therapeutic activity of the drug”. The primary objectives of sustained drug 
delivery are to ensure safety and enhancement of efficacy of drug with improved patient 
compliance. This delivery system is increasingly being used in the treatment of acute and 
chronic diseases as they maintain the concentration of drug in plasma above the minimum 
effective concentration and below the minimum toxic level for an extended period of time. 
Thus, sustained drug delivery results in optimum drug therapy with reduced frequency of 
dosing and side effects. Simply it can describe the slow release of a drug substance from a 
dosage form to maintain therapeutic response for extended period (8-12h) of time. Time 
depends on the dosage form. In oral form it is in hours, and in parenteral’s it is in days and 
Chapter1. Introduction 
                 DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLET Page 5 
months. Ex: Aspirin SR, Dextrin SR. In case of Controlled release dosage form the rate or 
speed at which the drug is released is controlled. Ex: Adalat CR (Nifidipine), Dynacirc CR 
(Isradipine). 
    The aim of any drug delivery system is to provide therapeutic amount of drug to 
appropriate site in the body to achieve immediate therapeutic response and to maintain the 
desired drug concentration. In the recent years sustained release (SR) dosage forms continue 
to draw attention in the research for improved patient compliance and decreased incidence of 
adverse drug reactions. Sustained release, sustained action, prolonged action, extended action 
are the terms used to identify drug delivery system that are designed to achieve a prolong 
therapeutic effect by continuously releasing medication over an extended period of time after 
administration of a single dose. 
 
Fig 1. Classification of dosage forms. 
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1.2.1 Advantages of Sustained release dosage forms5. 
I. Improved patient compliance: 
i. Less frequent dosing 
ii. Allows whole day coverage. 
II. Decreased local and systemic side effects. 
i. Decreased GIT irritation. 
ii. Decreased local inflammation. 
III. Better drug utilization. 
i. Decreased total amount of drug used. 
ii. Minimum drug accumulation on chronic dosing. 
IV. Improved efficiency in treatment. 
i. Uniform blood and plasma concentration. 
ii. Decreased fluctuation in drug level i.e. uniform pharmacological 
response.  
iii. Increased bioavailability of some drugs. 
V. Optimization of duration of action of drug. 
VI. Controlling the site release. 
VII. Economy.   
1.2.2 Disadvantages of Sustained release dosage forms. 
I. Increased variability among dosage units. 
II. Stability problems. 
III. Increased cost per unit dose. 
IV. More rapid development of tolerance. 
V. Need of additional patient education and counselling. 
1.2.3 Factors to be considered while formulating a sustained release dosage 
forms. 
I. Drug properties:  Stability, solubility, partition coefficient and protein binding 
are to be considered. 
II. Route of drug delivery:  Area of the body where drugs are applied or 
administered plays a vital role. 
III. Target sites:  To minimize side effects, it’s desired to maximize the fraction of 
dose applied. 
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IV. Acute or chronic dosing:  Cure, Control and length of drug therapy must be 
considered.  
V. The disease:   Pathological conditions play a significant role. 
VI. The patient:   Ambulatory/ bedridden, young or old, etc., must be considered5. 
1.2.4 TECHNIQUES FOR PREPARING SR FORMULATIONS5. 
 1.2.4.1 BASED ON DRUG MODIFICATION.  
Complex formation - The rate of dissolution of solid complex in biological fluids and 
rate of dissociation of complex in the solution are considered and they depend upon pH and 
composition of gastric and intestinal fluids.  
Drug-adsorbate preparation - In this product is insoluble. Drug availability is 
determined by rate of disabsorption. 
Pro drug synthesis - They are inactive and need enzymatic hydrolysis for regeneration. 
Solubility, absorption rate of pro drug must be lower than parent drug. 
Ion exchange resins - They are water insoluble, cross linked polymers containing salt 
forming groups. The drug is bound to the resin by using chromatographic column or by 
prolonged contact. 
 Drug release from this complex depends on pH & property of resin. Drug that is 
attached to the resin is released by exchanging with the ions present in the GIT 
                      Resin+ -Drug- +X-    --------------->      Resin+- X- + Drug, Example: Biphetamine. 
1.2.4.2 BASED ON DOSAGE FORM MODIFICATION. 
Micro encapsulation - It’s a process in which tiny particles are surrounded by uniform 
coating (microcapsule) or held in a matrix of polymer (microsphere.) Spray drying is used 
which involves rapid evaporation of the solvent from the drug surface. 
Chapter1. Introduction 
                 DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLET Page 8 
Barrier coating: In this one quarter of the granules are in non sustained form for 
sudden drug release, remaining part is coated for sustained release. Both these granules are 
filled in hard gelatine capsule or compressed in a tablet, and the release mechanism is by 
diffusion. Coating material used are fats, waxes. 
Matrix embedding - Drug is dispersed in a matrix of retardant material which may be 
encapsulated or compressed in a tablet. Mechanism of Drug Release from Matrix Tablets - As 
shown in Fig 2, in erodible matrices, polymer erosion from the surface of the matrix 
determines the drug release; whilst in hydrophilic matrices, formation of the gel layer and its 
dynamics as a function of time determines the drug release. Gel layer thickness, which 
determines the diffusion path length of the drug, corresponds to the distance between the 
diffusion and erosion fronts. As the swelling process proceeds, the gel layer gradually 
becomes thicker, resulting in progressively slower drug-release rates; however, due to 
continuous hydration, polymer disentanglement occurs from the surface of the matrix, 
resulting in a gradually decreasing depletion zone and an increased dissolution rate.Schematic 
drug release from matrix diffusion controlled-release drug delivery systems with the drug 
homogenously dispersed in: (a) an erodible polymer matrix; and (b) a hydrophilic, sellable polymer 
matrix. 
 
Fig 2. Mechanism of drug release from matrix tablets. 
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1.3 TABLETS5. 
1.3.1 Introduction5. 
    A tablet is a mixture of active substances and excipients, usually in powder form, 
pressed or compacted into a solid. The excipient include binders, glidants (Flow aids) and 
lubricants to ensure efficient tableting  disintegrants to ensure that the tablet breaks up in the 
digestive tract; sweeteners or flavours to mask the taste of bad-tasting active ingredients; and 
pigments to make uncoated tablets visually attractive. A coating may be applied to hide the 
taste of the tablet's components, to make the tablet smoother and easier to swallow, and to 
make it more resistant to the environment, extending its shelf life. Tablets may be swallowed 
whole or being chewed. Some are dissolved or dispersed in water before administration. Some 
are put in oral cavity, where the active ingredient is liberated at a predetermined rate. Implants 
may also be presented in form of tablet. 
Tablet may vary in shape and differ greatly in size and weight depending on the 
amount of medicinal substance and the intended mode of administration. The compressed 
tablet is the most popular dosage form in use today. About two-thirds of all are dispensed as 
solid dosage forms, and half of these are compressed tablets. A tablet can be formulated to 
deliver an accurate dosage to a specific site; it is usually taken orally, but can be administered 
sublingually, buccally, rectally or intra vaginally. The tablet is just one of the many forms that 
an oral drug can take such as syrups, elixirs, suspensions, and emulsions. Medicinal tablets 
were originally made in the shape of a disk of whatever colour their components determined, 
but are now made in many shapes and colors to help distinguish different medicines. Tablets 
are often stamped with symbols, letters, and numbers, which enable them to be identified. 
Sizes of tablets to be swallowed range from a few millimeters to about a centimetre. 
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1.3.2 VARIOUS TYPES OF TABLETS.  
1.3.2.1 ORAL TABLETS FOR INGESTION. 
These tablets are meant to be swallowed intact along with a sufficient quantity of 
potable water. Exception is chewable tablet. Over 90% of the tablets manufactured today are 
ingested orally. This shows that this class of formulation is the most popular worldwide and 
the major attention of the researcher is towards this direction. 
I. Standard compressed tablet. 
II. Multiple compressed tablet. 
i. Compression coated tablet. 
ii. Layered tablet. 
iii. Inlay tablet. 
III. Modified Release tablet. 
IV. Delayed action tablet. 
V. Targeted tablet. 
i. Floating tablet. 
ii.  Colon targeting tablet. 
VI. Chewable tablet. 
VII. Dispersible tablet. 
 
1.3.2.2 TABLETS USED IN THE ORAL CAVITY. 
The tablets under this group are aimed release API in oral cavity or to provide local 
action in this region. The tablets under this category avoids first-pass metabolism, 
decomposition in gastric environment, nauseatic sensations and gives rapid onset of action. The 
tablets formulated for this region are designed to fit in proper region of oral cavity. 
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I. Lozenges and troches. 
II. Sublingual tablet. 
III. Buccal tablet. 
IV. Dental cones. 
V. Mouth dissolved tablet. 
1.3.2.3 TABLETS ADMINISTERED BY OTHER ROUTES. 
These tablets are administered by other route except for the oral cavity and so the 
drugs are avoided from passing through gastro intestinal tract. These tablets may be inserted 
into other body cavities or directly placed below the skin to be absorbed into systemic 
circulation from the site of application. 
I. Vaginal tablet. 
1.3.2.4 TABLETS USED TO PREPARE SOLUTION. 
The tablets under this category are required to be dissolved first in water or other 
solvents before administration or application. This solution may be for ingestion or parenteral 
application or for topical use depending upon type of medicament used. 
I. Effervescent tablet 
II. Hypodermic tablet 
III. Soluble tablet 
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1.3.3 TABLET PROPERTIES5. 
Tablets can be made in virtually any shape, although requirements of patients and 
tableting machines mean that most are round, oval or capsule shaped. More unusual shapes 
have been manufactured but patients find these harder to swallow, and they are more 
vulnerable to chipping or manufacturing problems. Tablet diameter and shape are determined 
by the machine tooling used to produce them - a die plus an upper and a lower punch are 
required. This is called a station of tooling. The thickness is determined by the amount of 
tablet material and the position of the punches in relation to each other during compression. 
Once this is done, we can measure the corresponding pressure applied during compression. 
The shorter the distance between the punches, thickness, the greater the pressure applied 
during compression and sometimes the harder the tablet. Tablets need to be hard enough that 
they don't break up in the bottle, yet friable enough that they disintegrate in the gastric tract. 
Tablets need to be strong enough to resist the stresses of packaging, shipping and 
handling by the pharmacist and patient. The mechanical strength of tablets is assessed using a 
combination of (i) simple failure and erosion tests, and (ii) more sophisticated engineering 
tests. The simpler tests are often used for quality control purposes, whereas the more complex 
tests are used during the design of the formulation and manufacturing process in the research 
and development phase. Standards for tablet properties are published in the various 
international pharmacopeias (USP/NF, EP, JP, etc). Lubricants prevent ingredients from 
clumping together and from sticking to the tablet punches or capsule filling machine. 
Lubricants also ensure that tablet formation and ejection can occur with low friction between 
the solid and die wall. Common minerals like talc or silica, and fats, e.g. vegetable stearin, 
magnesium stearate or stearic acid are the most frequently used lubricants in tablets or hard 
gelatin capsules. 
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1.3.4 Advantages of tablet as a dosage form. 
I. Large scale manufacturing is feasible in comparison to other dosage forms. 
Therefore, economy can be achieved. 
II. Inaccuracy of dose is maintained since tablet is a solid unit dosage form. 
III. Tailor made release profile can be achieved. 
IV. Longer expiry period and minimum microbial spillage owing to lower moisture 
content. 
V. As tablet is not a sterile dosage form, stringent environmental conditions are not 
required in the tablet department. 
VI. Ease of packaging (blister or strip) and easy handling over liquid dosage form. 
VII. Easy to transport in bulk. Emergency supply supplies can be carried by patients. 
VIII. Organoleptic properties (taste, appearance and odour) are best improved by 
coating of tablet. 
IX. Product identification is easy and markings done with the help of grooved punches 
and printing with edible ink. 
X. Different types of tablets are available like buccal, floating, colon targeting, 
effervescent, dispersible, soluble, and chewable, etc. 
XI. In composition to parenteral dosage form, a doctor or a nurse is not required for 
administration. I.e. self administration is possible. 
XII. In comparison to capsules, tablets are more tamperproof. 
XIII. Tablets are easy and convenient to use. 
XIV. Tablets provide an accurately measured dosage in a convenient portable package, 
and can be designed to protect unstable medications or disguise unpalatable 
ingredients.  
XV. Manufacturing processes and techniques can provide tablets special properties, for 
example enteric coatings or sustained release formulations. 
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1.3.5 Disadvantages of tablet as a dosage form. 
I. Some drugs may be unsuitable for administration by the oral route. 
II. Bioavailability of some drugs may be low due to poor absorption from the gastric 
tract. Such drugs may need to be given in very high doses or by injection. 
III. It is difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
IV. Difficult to formulate a drug with poor wettability, slow dissolution into a tablet. 
1.3.6 Excipient and their functionalities. 
Excipient means any component other than the active pharmaceutical ingredient(s) 
intentionally added to the formulation of a dosage form. Many guidelines exist to aid in 
selection of nontoxic excipients such as IIG (Inactive Ingredient Guide), GRAS (Generally 
Regarded as Safe), Handbook of Pharmaceutical Excipients and others. While selecting 
excipients for any formulation following things should be considered wherever possible: keep 
the excipients to a minimum in number minimize the quantity of each excipient and 
multifunctional excipients may be given preference over unifunctional excipients. 
Excipients play a crucial role in design of the delivery system, determining its quality 
and performance. Excipients though usually regarded as nontoxic there are examples of 
known excipient induced toxicities which include renal failure and death from diethylene 
glycol, osmotic diarrhoea caused by ingested mannitol, hypersensitivity reactions from lanolin 
and cardio toxicity induced by propylene glycol. 
Excipients are chosen in tablet formulation to perform a variety of functions like, 
I. For providing essential manufacturing technology functions (Binders, glidants, 
lubricants may be added), 
II. For enhancing patient acceptance (Flavors, colorants may be added), 
III. For providing aid in product identification (Colorants may be added), 
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IV. For Optimizing or modifying drug release (Disintegrants, hydrophilic polymers, 
wetting agents, biodegradable polymers may be added), 
V. For enhancing stability (Antioxidant, UV absorbers may be added) 
Table 1. Various excipients used in tablet formulation and their functionalities. 
EXCIPIENT FUNCTION 
Diluents or Fillers Diluents make the required bulk of the tablet when the drug 
dosage itself is inadequate to produce tablets of adequate weight 
and size. 
Binders or Granulating 
agents or Adhesives 
Binders are added to tablet formulations to add cohesiveness to 
powders, thus providing the necessary bonding to form granules, 
which under compaction form a cohesive mass or a compact 
which is referred to as a tablet. 
Disintegrants A disintegrant is added to most tablet formulations to facilitate a 
breakup or disintegration of the tablet when placed in an 
aqueous environment. 
Lubricants Lubricants are intended to reduce the friction during tablet 
formation in a die and also during ejection from die cavity. 
Antiadherents Antiadherents are added to reduce sticking or adhesion of any of 
the tablet granulation or powder to the faces of the punches or to 
the die wall. 
Glidants Glidants are intended to promote the flow of tablet granulation 
or powder mixture from hopper to the die cavity by reducing 
friction between the particles. 
MISCELLANEOUS  
Wetting agents Wetting agents are added to tablet formulation to aid water 
uptake during disintegration and assist drug dissolution. 
Dissolution retardants Dissolution retardants as the name suggest, retards the 
dissolution of active pharmaceutical ingredient(s). 
Dissolution enhancers Dissolution enhancers as the name suggest, enhance the 
dissolution rate of active pharmaceutical ingredient(s). 
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Adsorbents Adsorbents are capable of retaining large quantities of liquids 
without becoming wet; this property of absorbent allows many 
oils, fluid extracts and eutectic melts to be incorporated into 
tablets. 
Buffers Buffers are added to provide suitable micro environmental pH to 
get improved stability and / or bioavailability. 
Antioxidants Antioxidants are added to maintain product stability, they act by 
being preferentially oxidized and gradually consumed over shelf 
life of the product. 
Chelating agents Chelating agents are added to protect against autoxidation; they 
act by forming complexes with the heavy metal ions which are 
often required to initiate oxidative reactions. 
Preservatives Preservatives are added to tablet formulation in order to prevent 
the growth of micro-organisms. 
Colours Colours are added to tablet formulation for following purposes: 
to disguise off colour drugs, product identification and for 
production of more elegant product. 
Flavours Flavours are added to tablet formulation in order to make them 
palatable enough in case of chewable tablet by improving the 
taste. 
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2. AIM & OBJECTIVES 
                  Due to various advantages of controlled release drug delivery system in 
present study, an attempt was made to formulate controlled release drug delivery system for 
Ibuprofen & to find the effect of different polymers such as stearic acid, glyceryl behnate and 
xanthan gum along with different excipients such as mannitol and dicalcium phosphate and 
with a view to obtain a better control over the release of the drug from the delivery system 
and for prolong the drug action in the therapeutic range and thereby reducing the dose 
frequency. 
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3. PLAN OF WORK 
I. Active Pharmaceutical Ingredient (API) and excipients characterization to prepare 
solid oral dosage form of Ibuprofen controlled Release tablet. 
II. To carry out preformulation studies. 
a. Solubility. 
b. Angle of repose. 
c. Bulk density. 
e. Tapped density. 
f. Compressibility index. 
g. Haussner’s ratio. 
 
III. To prepare and develop the dosage form of ibuprofen controlled Release tablet by wet 
granulation method. 
IV. To evaluate the formulated tablets for their physicochemical   characteristics such as: 
a. Content uniformity. 
b. Hardness. 
c. Thickness. 
d. Weight variation. 
e. Friability. 
V. Invitro Dissolution studies. 
VI. Stability studies. 
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4. LITERATURE REVIEW 
                R. Patel et al. (2010)6 reviewed ibuprofen, a weekly acidic, non-steroidal anti 
inflammatory drug having high permeability through stomach but due to its solubility 
limitation it can’t enter in to systemic circulation and gastric empting time ranging from 30 
min to 2 hr, after this time ibuprofen goes in to small intestine where it is solubilise but can’t 
permeate through its membrane. To improve dissolution of such drug is challenging and 
rational. In present investigation, dissolution of ibuprofen improves by preparing floating 
granules. Floating is requiring for increasing residence time of granules in stomach. 
Ibuprofen must have to remain in stomach because it is mostly permeable through it. 
Multipurpose floating formulations was developed by preparing immediate release (for 
loading dose) granules containing gelucire 44/14 and sustained release floating granules 
containing gelucire 43/01 and small amount of gelucire 44/14. Amount of gelucire 44/14 and 
gelucire 43/01 was optimized using factorial design. Amount of gelucire 44/14 (X1) and 
amount of Gelucire 43/01 (X2) selected as independed variable. t100% (time require to 
dissolve 100 % drug) and total floating time chosen as response or depended variable. 
Release kinetic of ibuprofen studied by applying different model (zero order, first order, 
higuchi, korsmeyer-peppas, Hixson crowell and weibull). In optimized formulation, Granules 
remain floated for 3 hrs. and gave 100% drug release in 150 minute. 
  
      S. Chandran et. al. (2008)7 studied Controlled release preparations have been 
reported to reduce the gastro irritant and ulcerogenic effects of non steroidal antiinflammatory 
drugs. In the present study, an attempt was made to develop matrix tablet-based controlled 
release formulations of ibuprofen, using ethyl cellulose as the rate-controlling polymer. In 
order to prevent initial release of the drug in the acidic environment of the stomach, cellulose 
acetate phthalate was incorporated in the matrix in varying amounts. It was found that with 
increasing the proportion of ethyl cellulose in the matrix, the drug release was extended for 
14-16 h. Incorporation of cellulose acetate phthalate in ethyl cellulose matrix provided very 
low initial release of the drug in the first 2-3 h followed by enhanced release rate in alkaline 
medium owing to the high solubility of cellulose acetate phthalate at basic pH which led to 
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creation of a porous matrix. It was concluded that combination of cellulose acetate phthalate 
with ethyl cellulose in the matrix base can be an effective means of developing a controlled 
release formulation of ibuprofen with very low initial release followed with controlled release 
up to 14-16 h. 
                G.S. Sonar et al. (2007)8 The purpose of this investigation was to prepared a 
gastroretentive floating drug delivery system (GFDDS) of the hydrophilic polymer hydroxy 
propyl methyl cellulose (HPMC), gas generating agent sodium bicarbonate and citric acid. A 
32 factorial design was applied systematically; the amount of citric acid (X1) and amount of 
HPMC K100M (X2) were selected as independent variables. The time required for 50% drug 
release (t50%), percentage drug release at 12 hours (Q12) and percentage of drug release at 6 
hours (Q6) were selected as dependent variables. The granules were prepared by wet 
granulation method and evaluated for their granules properties. The drug release from the 
tablets was sufficiently sustained followed the model controlled mechanism of  tablet. 
 
                S.S. Krishna et al. (2006)9 developed to extend the GI residence time of the dosage 
form and control the release of Ibuprofen using mucoadhesive tablet to achieve controlled 
plasma level of the drug which is especially useful after 8 to 12 weeks of monotherapy using 
conventional dosage forms when dose is doubled and plasma level also doubles. Direct 
compression method using simplex lattice design, Rosiglitazone maleate, Carbopol 934, 
Ethylcellulose (EC; 18-22 cP; Ethoxyl content 48-49.5%)andCellulose Acetate Phthalate 
followed by optimization of the evaluation parameters was employed to get final optimized 
formulation. The optimized formulation showed a mucoadhesive strength >40 gm-f, and a 
mucoadhesion time >12 hours with release profile closer to the target release. 
 
   M. H. Shoaib et al. (2005)10 developed a once-daily sustained release matrix tablet 
of ibuprofen using hydroxypropyl methylcellulose (HPMC) as release controlling factor and 
to evaluate drug release parameters as per various release kinetic models. In order to achieve 
required sustained release profile tablets were directly compressed using Avicel pH 101 and 
Magnesium stearate. The formulated tablets were also characterized by physical and chemical 
parameters and results were found in acceptable limits. Different dissolution models were 
applied to drug release data in order to evaluate release mechanisms and kinetics. Criteria for 
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selecting the most appropriate model was based on linearity (coefficient of correlation). The 
drug release data fit well to the Higuchi expression. Drug release mechanism was found as a 
complex mixture of diffusion, swelling and erosion. 
                  P. Thapa et al. (2005)11 formulated control release oral delivery system and to 
investigate the influence of different diluents, Carbopol 934P concentration and granulation 
technique in the release of poorly water-soluble drug (Ibuprofen) from Carbopol 934P matrix 
tablets. Matrix tablets were prepared by direct compression, wet granulation and dry 
granulation method at different polymer concentration using lactose, dibasic calcium 
phosphate (DCP), microcrystalline cellulose (MCC) and starch as diluents. Dissolution 
studies were carried out in 900 ml phosphate buffer pH 7.4 using USP-apparatus I. At 5% 
Carbopol 934P concentration, the t50% was found in the rank order of tablets containing 
starch<MCC<DCP<lactose. 
B. Arica et. al.  (2005)12 studied the irritation effects of ibuprofen, a widely 
used non-steroidal anti-inflammatory drug (NSAID), were evaluated on mouse gastric and 
duodenal mucosa when suspended in 0.5% (w/v) sodium carboxy methylcellulose (NaCMC) 
solution and loaded in alginate beads. The ionotropic gelation method was used to prepare 
controlled release alginate beads of ibuprofen. The influence of various formulation factors on 
the encapsulation efficiency, as in vitro drug release and micromeritic properties, was 
investigated. Other variables included the alginate concentration, percentage drug loading and 
stirring speed during the microencapsulation process.  
S.Turner et. al. (2005)13 evaluated in vitro the release characteristics of a 
novel 600mg controlled release tablet formulation of ibuprofen using dissolution studies and 
in vivo human pharmacokinetic studies. In vitro analysis showed the formulation was capable 
of releasing ibuprofen in a controlled manner over 12 hours. In vivo analysis showed the 
formulation performed in a manner similar to that demonstrated by dissolution studies, 
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resulting in a biphasic profile of ibuprofen release. The available literature of ibuprofen 
suggests that such a biphasic profile is an appropriate rate of release for achieving the desired 
onset of action and prevention of breakthrough symptoms in vivo. 
R. Canaparo et. al. (2000)14 Described a specific method for the 
simultaneous determination of S-(+)Ibuprofen and R-(-)Ibuprofen enantiomers in human 
plasma. Adopting a high-performance liquid chromatographic (HPLC) system with 
spectrofluorometer detector, the compounds were extracted from plasma in alcohol medium 
and were separated on C18 column, using a solution of acetonitrile– water–acetic acid–
triethylamine as mobile phase. The limit of quantitation was 0.1 mg/mL for both compounds. 
The method was validated by intra-day assays at three concentration levels and was used in a 
kinetic study in healthy volunteers. During the study we carried out inter-day assays to 
confirm the feasibility of the method. 
M. Rafiee-Tehrani et al. (1999)15 studied the need for controlled release 
(CR) formulations of ibuprofen tablet, is well recognized. The purpose of this study was to 
develop an air suspension method, using a laboratory scale fluidized bed drier to coat the 
ibuprofen granules. Different polymers including, Eudragits L100, S100, RL100, RS100, 
L100+S100 (1:1), RL100+RS100 (1:1), ethyl cellulose (EC) and Eudragit RS100+EC (1:1) 
were utilized. The drug release medium consisted of buffer pH 1.2 for 1st 2h, buffer pH 4.5 
for 2nd 2h and buffer pH 7.5 for remaining period of time in all experiments, but the release 
behavior of the drug from some formulations was also studied using distilled water. Of the 
polymers investigated, Eudragit RS100, EC, Eudragit S100 and Eudragit RS100+EC (1:1) 
exhibited proper release characteristics when used as coating materials. The release patterns 
were analyzed from the standpoint of diffusion-controlled processes and as first-order 
kinetics. 
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5.  MATERIALS & INSTRUMENTS USED. 
 
 
Table 2. List of materials. 
Sl. 
No. 
Name of  the ingredients Category 
                         
Manufacturer 
1 Ibuprofen Drug         Matrix.lab’s 
2 Glyceryl behenate Polymer Signet chemicals 
3 Xanthan gum Polymer Signet chemicals 
4 Stearic acid Polymer Indchem international 
5 Mannitol Diluents            Colorcon 
6 Dicalcium phosphate Diluents KMV Enterprises 
7 Magnesium Stearate Lubricant Signet chemicals 
8 Povidone K30 Binding agent Signet chemicals 
9 IPA(Iso propyl alcohol) Solvent Indchem international 
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Table 3. List of equipments. 
 
 
 
 
 
 
 
 
Sl. No. Equipment Manufacturer 
1. Electronic balance Citizen Pvt. Ltd,Mumbai 
2. Tapped density tester Electro lab 
3. pH meter Inolab 
4. Dissolution test apparatus Electro lab USP 
5. UV-VISIBLE Spectrophotometer Shimadzu 
6. Stability chambers Thermo lab 
7. Hot air oven Lab-shop corporation, Mumbai 
8. Monsanto hardness tester Cadmach 
9. Roche friability tester Labhosp, Mumbai 
10.                          Mesh Retsec 
11. Mechanical stirrer Remi motors , Bombay 
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5.1. DRUG PROFILE16,17 
Drug name: IBUPROFEN 
 
 
Fig 3. Chemical structure of (RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid 
 CHEMICAL AND PHYSICAL PROPERTIES: 
      Molecular weight -  206.28. 
      Molecular formula -  C13H18O2. 
      Description - White or almost white, crystalline powder or colorless crystals. 
Melting point - 76 °C (169 °F). 
Molecular mass - 206.29 gm/mol. 
Solubility - Insoluble in water, freely soluble in ethanol and chloroform. 
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 PHARMACOKINETIC DATA16,17.  
Bioavailability - 49 – 73 %. 
Protein binding – 99 %, 
Metabolism – Hepatic. 
Half-life – 1.8 - 2 h. 
Excretion – Renal. 
DOSE :          800mg-3200mg per day. 
 MECHANISM OF ACTION18,19 
                  Nonsteroidal anti-inflammatory drugs such as ibuprofen work 
by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic 
acid to prostaglandin H2 (PGH2). PGH2, in turn, is converted by other enzymes to several 
other prostaglandins (which are mediators of pain, inflammation, and fever) and 
to thromboxane A2 (Which stimulates platelet aggregation, leading to the formation of blood 
clots). Like aspirin, indomethacin, and most other NSAIDs, ibuprofen is considered a 
nonselective COX inhibitor; that is, it inhibits two isoforms of cyclo-oxygenase, COX-
1 and COX-2. The analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appears 
to be achieved mainly through inhibition of COX-2, whereas inhibition of COX-1 would be 
responsible for unwanted effects onplatelet aggregation and the gastrointestinal 
tract.[31] However, the role of the individual COX isoforms in the analgesic, anti-
inflammatory, gastric damage effects of NSAIDs is uncertain and different compounds cause 
different degrees of analgesia and gastric damage. In order to achieve the beneficial effects of 
ibuprofen and other NSAIDS without gastrointestinal ulceration and bleeding, selective COX-
2 inhibitors were developed to inhibit the COX-2 isoform without inhibition of COX-1. 
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 ADVERSE EFFECTS18. 
  Common adverse effects are nausea, dyspepsia, gastrointestinal ulceration/bleeding, 
raised liver enzymes,  diarrhea,  constipation,  epistaxis,  headache,  dizziness, priapism, rash, 
salt, fluid retention, and hypertension. A study from 2010 has shown regular use of NSAIDs 
was associated with an increase in hearing loss. Infrequent adverse effects includes 
esophageal ulceration, heart failure, hyperkalemia, renal impairment, confusion, 
and bronchospasm. Ibuprofen appears to have the lowest incidence of digestive adverse drug 
reactions (ADRs) of all the nonselective NSAIDs. However, this holds true only at lower 
doses of ibuprofen, so OTC preparations of ibuprofen are, in general, labeled to advise a 
maximum daily dose of 1,200 mg. 
 PHOTOSENSITIVITY18. 
As with other NSAIDs, ibuprofen has been reported to be 
a photosensitising agent. However, this only rarely occurs with ibuprofen and it is considered 
to be a very weak photosensitising agent when compared with other members of the 2-
arylpropionic acid class. This is because the ibuprofen molecule contains only a 
single phenyl moiety and no bond conjugation, resulting in a very weak chromophore system 
and a very weak absorption spectrum, which does not reach into the solar spectrum. 
 CARDIOVASCULAR RISK18. 
Along with several other NSAIDs, ibuprofen has been implicated in elevating the risk 
of myocardial infarction (Heart attack), in particular, among those chronically using high 
doses.   
 INTERACTIONS18. 
Drinking alcohol when taking ibuprofen increases risk of stomach bleeding. 
According to the U.S. Food and Drug Administration, ibuprofen can interfere with the 
antiplatelet effect of low-dose aspirin (81 mg per day), potentially rendering aspirin less 
effective when used for cardioprotection and stroke prevention. Allowing sufficient time 
between doses of ibuprofen and immediate release aspirin can avoid this problem. The 
recommended elapsed time between a 400 mg dose of ibuprofen and a dose of aspirin 
depends on which is taken first. It would be 30 min or more for ibuprofen taken after 
immediate release aspirin, and 8 hours or more for ibuprofen taken before immediate release 
aspirin. However, this timing cannot be recommended for enteric-coated aspirin. But, if 
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ibuprofen is taken only occasionally without the recommended timing, the reduction of the 
cardioprotection and stroke prevention of a daily aspirin regimen is minimal.  
ERECTILE DYSFUNCTION RISK18. 
A 2005 study linked long term (Over 3 months) use of NSAIDs, including ibuprofen, 
with a 1.4 times increased risk of erectile dysfunction.[21] [22] The report by Kaiser Permanente 
and published in the Journal of Urology, considered that "regular non-steroidal anti-
inflammatory drug use is associated with erectile dysfunction beyond what would be expected 
due to age and other condition".[23] The director of research for Kaiser Permanente added that 
"There are many proven benefits of non steroidals in preventing heart disease and for other 
conditions. People shouldn't stop taking them based on this observational study. However, if a 
man is taking this class of drugs and has ED, it's worth a discussion with his doctor. 
 OVERDOSE18,19. 
Ibuprofen overdose has become common since it was licensed for OTC use. There are 
many overdose experiences reported in the medical literature, although the frequency of life-
threatening complications from ibuprofen overdose is low.[24] Human response in cases of 
overdose ranges from absence of symptoms to fatal outcome in spite of intensive care 
treatment. Most symptoms are an excess of the pharmacological action of ibuprofen and 
include abdominal pain, nausea, vomiting, drowsiness, dizziness, headache, tinnitus, 
and nystagmus. Rarely, more severe symptoms such as gastrointestinal 
bleeding, seizures, metabolic acidosis,  hyperkalaemia,  hypotension,  bradycardia, 
 tachycardia,  atrial fibrillation, coma, hepatic dysfunction, acute renal 
failure, cyanosis, respiratory depression, and cardiac arrest have been reported. The severity 
of symptoms varies with the ingested dose and the time elapsed; however, individual 
sensitivity also plays an important role. Generally, the symptoms observed with an overdose 
of ibuprofen are similar to the symptoms caused by overdoses of other NSAIDs. 
There is little correlation between severity of symptoms and measured ibuprofen 
plasma levels. Toxic effects are unlikely at doses below 100 mg/kg, but can be severe above 
400 mg/kg (around 150 tablets of 200 mg units for an average man);[26] however, large doses 
do not indicate the clinical course is likely to be lethal.[27] It is not possible to determine a 
precise lethal dose, as this may vary with age, weight, and concomitant diseases of the 
individual patient. 
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Therapy is largely symptomatic. In cases presenting early, gastric decontamination is 
recommended. This is achieved using activated charcoal; charcoal adsorbs the drug before it 
can enter the systemic circulation. Gastric lavage is now rarely used, but can be considered if 
the amount ingested is potentially life-threatening, and it can be performed within 60 min of 
ingestion. Emesis is not recommended. The majority of ibuprofen ingestions produce only 
mild effects and the management of overdose is straightforward. Standard measures to 
maintain normal urine output should be instituted and renal function monitored.[26] Since 
ibuprofen has acidic properties and is also excreted in the urine, forced alkaline diuresis is 
theoretically beneficial. However, because ibuprofen is highly protein-bound in the blood, 
there is minimal renal excretion of unchanged drug. Forced alkaline diuresis is, therefore, of 
limited benefit. Symptomatic therapy for hypotension, GI bleeding, acidosis, and renal 
toxicity may be indicated. On occasion, close monitoring in an intensive care unit for several 
days is necessary. If a patient survives the acute intoxication, he or she will usually experience 
no late sequelae. 
DETECTION IN BODY FLUIDS18,19. 
Ibuprofen may be quantitated in blood, plasma, or serum to demonstrate the presence 
of the drug in a person having experienced an anaphylactic reaction, confirm a diagnosis of 
poisoning in hospitalized patients, or assist in a medicolegal death investigation. A nomogram 
that relates the ibuprofen plasma concentration, time since ingestion, and risk of developing 
renal toxicity in overdose patients has been published.  
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5.2 EXCIPIENTS PROFILE20. 
1. Stearic Acid. 
1. Synonyms 
Cetylacetic acid; Crodacid; E570; Edenor; Emersol; Hystrene; Industrene; Kortacid 1895; 
Pearl Steric; Pristerene; stereophanic acid; Tegostearic. 
 
2. Functional Category 
Emulsifying agent; solubilizing agent; tablet and capsule lubricant. 
 
3. Applications in Pharmaceutical Formulation or Technology 
Stearic acid is widely used in oral and topical pharmaceutical formulations. It is mainly used 
in oral formulations as a tablet and capsule lubricant.Although it may also be used as a binder 
or in combination with shellac as a tablet coating.It has also been suggested that stearic acid 
may be used as a sustained-release drug carrier.In topical formulations, stearic acid is used as 
an emulsifying and solubilizing agent. When partially neutralized with alkalis or 
triethanolamine, stearic acid is used in the preparation ofcreams. The partially neutralized 
stearic acid forms a creamy base when mixed with 5–15 times its own weight of aqueous 
liquid; the appearance and plasticity of the cream being determined by the proportion of alkali 
used.Stearic acid is used as the hardening agent in glycerin suppositories. 
Stearic acid is also widely used in cosmetics and food products. 
 
4. Description 
Stearic acid is a hard, white or faintly yellow-colored, somewhat glossy, crystalline solid or a 
white or yellowish white powder. It has a slight odor and taste suggesting tallow. 
 
Chapter 5. Material & methods 
                         DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLET Page 31 
5. Solubility: 
Freely soluble in benzene, carbon tetrachloride, chloroform, and ether; soluble in ethanol 
(95%), hexane, and propylene glycol; practically insoluble in water. 
 
6. Stability and Storage Conditions 
Stearic acid is a stable material; an antioxidant may also be added to it. The 
bulk material should be stored in a well-closed container in a cool, dry place. 
 
7. Incompatibilities 
Stearic acid is incompatible with most metal hydroxides and may be incompatible with 
oxidizing agents.Insoluble stearates are formed with many metals; ointment bases made with 
stearic acid may show evidence of drying out or lumpiness due to such a reaction when 
compounded with zinc or calcium salts.A number of differential scanning calorimetry studies 
have investigated the compatibility of  stearic acid with drugs. Although such laboratory 
studies have suggested incompatibilities,e.g. with naproxen, they may not necessarily be 
applicable to formulated products.Stearic acid has been reported to cause pitting in the film 
coating of tablets coated using an  aqueous film-coating technique; the pitting was found to be 
a function of the melting point of the stearic acid. 
 
8. Safety 
Stearic acid is widely used in oral and topical pharmaceutical formulations; it is also used in 
cosmetics and food products. Stearic acid is generally regarded as a nontoxic and nonirritant 
material. However, consumption of excessive amounts may be harmful. 
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2. GLYCERYL BEHENATE. 
Non-proprietary names - BP:          Glycerol dibehenate, PhEur:     Glycerol dibehenate and 
USP-NF: Glyceryl behenate. 
Synonyms - 2, 3-dihydroxypropyl docosanoate, 2, 3-dihydroxypropyl ester, glycerol behenate 
and glyceroli dibehenas.  
Empirical Formula and Molecular Weight - Glyceryl dibehenate is a mixture of glycerol 
esters. The PhEur 6.0 describes glyceryl dibehenate as a mixture of diacylglycerols, mainly 
dibehenoyl glycerol, together with variable quantities of mono- and triacylglycerols. The 
USP32–NF27 describes glyceryl behenate as a mixture of glycerides of fatty acids, mainly 
behenic acid. It specifies that the content of 1-monoglycerides should be 12.0–18.0%. 
Functional Category - Coating agent, tablet binder, tablet and capsule lubricant, thickening 
agent and viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology - Glyceryl behenate is used in 
cosmetics, foods, and oral pharmaceutical formulations. In pharmaceutical formulations, 
glyceryl behenate is mainly used as a lubricant in the preparation of oral tablets and capsules. 
It has good binding properties, it does not affect tablet hardness and is unaffected by mixing 
or production parameters. Glyceryl behenate has been investigated for the encapsulation of 
various drugs such as retinoids. It has also been investigated for use in the preparation of 
sustained-release tablets as a matrix-forming agent for the controlled release of water-soluble 
drugs, and it can also be used as a hot-melt coating agent sprayed onto a powder or drug-
loaded sugar beads and granules. It may also be incorporated via extrusion/spheronization into 
pellets, which can be further compressed into tablets. Glyceryl behenate is used in oral 
enteric-coated pellets, powders and suspensions. It is also used in controlled, extended-release 
and orally disintegrating tablets. For oral preparations, glyceryl behenate forms a lipidic 
matrix for sustained-release formulations. It has been used along with acid-soluble or 
swellable polymers to mask the bitter or unpleasant taste of the medicament with improved 
palatability. Glyceryl behenate has been used for the preparation of ophthalmic inserts. In 
cosmetics, glyceryl behenate is used as a skin conditioning agent, emollient and viscosity 
increasing agent in emulsions. It also improves the heat stability of emulsions and is a 
gelifying agent for various oils. For topical formulations, it is used as a thickening agent for 
oily phases. It is also used as a surfactant or emulsifying agent. 
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Uses of glyceryl behenate - 
                 Use                                                                           Concentration (%) 
Lipophilic matrix or coating for sustained-released 
Tablets and capsules                                                                         >10.0 
Tablet and capsule lubricant                                                          1.0–3.0 
Viscosity-increasing agent in silicon gels (cosmetics)                 1.0–15.0 
Viscosity increasing agent in w/o or o/w emulsions                      1.0-5. 
Description - Glyceryl behenate occurs as a fine white-yellow powder, as a hard waxy mass 
or pellet and as white or almost white unctuous flakes. It has a faint odor. 
Solubility - Soluble when heated in chloroform and dichloromethane, also in many organic 
solvents, slightly soluble in hot ethanol (96%), practically insoluble in cold ethanol (95%), 
hexane, mineral oil and water. 
Stability and Storage Conditions - Glyceryl behenate should be stored in a tightly closed 
container, at a temperature less than 35°C. 
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3.Xanthan gum 
 
 Nonproprietary Names: BP: Xanthan gum,PhEur: Xanthani gummi,USPNF: Xanthan gum 
 Synonyms: 
Corn sugar gum, polysaccharide , Xantura, Xanthan gum  
 Empirical Formula and Molecular Weight(C35H49O29)n Approximately 2 _ 106.The 
USPNF 23 describes xanthan gum as a high molecularweight polysaccharide gum. It contains 
D-glucose and Dmannoseas the dominant hexose units, along with Dglucuronic acid, and is 
prepared as the sodium, potassium, or 
calcium salt. 
 Functional Category: Stabilizing agent; suspending agent; viscosity-increasing agent. 
 Applications in Pharmaceutical Formulationor Technology: Xanthan gum is widely used in 
oral and topical pharmaceutical formulations, cosmetics, and foods as a suspending and 
stabilizing agent. It is also used as a thickening and emulsifying agent. It is nontoxic, 
compatible with most other pharmaceutical ingredients, and has good stability and viscosity 
properties over a wide pH and temperature range; 
 Xanthan gum gels show pseudoplastic behavior,the shear thinning being directly proportional 
to the shear rate.The viscosity returns to normal immediately on release of shear stress. When 
xanthan gum is mixed with certain inorganic suspending agents, such as magnesium 
aluminum silicate, or organic gums, synergistic rheological effects occur. In general, mixtures 
of xanthan gum and magnesium aluminum silicate in ratios between 1 : 2 and 1 : 9 produce 
the optimum properties.Similarly, optimum synergistic effects are obtained with xanthan gum 
: guar gum ratios between 3 : 7 and 1 : 9.Although primarily used as a suspending agent, 
xanthan gum has also been used to prepare sustained-release matrix tablets.Controlled-release 
tablets of diltiazem hydrochlorideprepared using xanthan gum have been reported to sustain 
the drug release in a predictable manner and the drug release profiles of these tablets were not 
affected by pH and agitation rate. Xanthan gum has been incorporated in an ophthalmic 
liquid dosage form, which interacts with mucin, thereby helping in the prolonged retention of 
the dosage form in the precorneal area.Recent studies have revealed that xanthan gum can 
also be used as an excipient for spray-drying and freeze-drying processes for better 
results.Xanthan gum can be used to increase the bioadhesive strength in vaginal formulations 
and as a binder in colon specific drug delivery systems. Xanthan gum is also used as a 
hydrocolloid in the food industry, and in cosmetics it has been used as a thickening agent in 
shampoo. 
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 Description: 
Xanthan gum occurs as a cream- or white-colored, odorless,free-flowing, fine powder. 
 
 
 Pharmacopeial Specifications 
 
Table I: Pharmacopeial specifications for xanthan gum. 
Test PhEur 2005 USPNF 23 
Identification þ þ 
Characters þ — 
pH 6.0–8.0 — 
Viscosity 5600 mPas 5600 mPas 
Propan-2-ol 4750 ppm 40.075% 
Other polysaccharides þ — 
Loss on drying 415.0% 415.0% 
Total ash 6.5–16.0% 6.5–16.0% 
Microbial contamination þ þ 
Bacteria 4103/g — 
Fungi 4102/g — 
Pyruvic acid — 41.5% 
Arsenic — 43 mg/g 
Lead — 45 mg/g 
Heavy metals — 40.003% 
Organic volatile impurities — þ 
Assay — 91.0–108.0% 
10 Typical Properties 
Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous 
solution. 
Freezing point: 08C for a 1% w/v aqueous solution. 
Heat of combustion: 14.6 J/g (3.5 cal/g) 
Melting point: chars at 2708C. 
Particle size distribution: various grades with different particle sizes are available; for 
example, 100% less than 180 mm in size for Keltrol CG; 100% less than 75 mm in size for 
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Keltrol CGF; 100% less than 250 mm, 95% less than 177 mm in size for Rhodigel; 100% less 
than 177 mm, 92% less than 74 mm in size for Rhodigel 200. 
Refractive index: nD 20 = 1.333 for a 1% w/v aqueous solution. 
Solubility: practically insoluble in ethanol and ether; soluble in cold or warm water. 
Specific gravity: 1.600 at 258C 
Viscosity (dynamic): 1200–1600 mPa s (1200–1600 cP) for a1% w/v aqueous solution at 
258C. 
 Stability and Storage Conditions: Xanthan gum is a stable material. Aqueous solutions are 
stable over a wide pH range (pH 3–12), although they demonstrate maximum stability at pH 
4–10 and temperatures of 10–608C. 
Xanthan gum solutions of less than 1% w/v concentration may be adversely affected by 
higher than ambient temperatures: for example, viscosity is reduced. Solutions are also stable 
in the presence of enzymes, salts, acids, and bases. The bulk material should be stored in a 
well-closed container in a cool, dry place. 
 Safety: Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and food products and is generally regarded as nontoxic and nonirritant at the 
levels employed as a pharmaceutical excipient. The estimated acceptable daily intake for 
xanthan gum has been set by the WHO at up to 10 mg/kg body-weight.(22) 
LD50 (dog, oral): >20 g/kg(22) 
LD50 (rat, oral): >45 g/kg 
LD50 (mouse, oral): >1 g/kg(23) 
LD50 (mouse, IP): >50 mg/kg(23) 
LD50 (mouse, IV): 100–250 mg/kg 
Handling Precautions: Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Eye protection and gloves are recommended. 
 Regulatory Status: GRAS listed. Accepted for use as a food additive in Europe. Included in 
the FDA Inactive Ingredients Guide (oral solutions, suspensions, and tablets; rectal and 
topical preparations). 
Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of 
Acceptable Non-medicinalIngredients. 
 Related Substances: Ceratonia; guar gum. 
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4. MANNITOL. 
Non-proprietary names -  BP:  Mannitol, JP:  D-Mannitol, PhEur: Mannitol and USP: 
    Mannitol. 
Synonyms - Cordycepic acid, C*PharmMannidex,  E421, emprove, manna sugar,  D-mannite, 
mannite, mannitolum, mannogem and pearlitol. 
Chemical name and CAS Registry Number - D-Mannitol [69-65-8]. 
Empirical Formula and Molecular Weight - C6H14O6 and 182.17. 
Functional Category - Diluent, plasticizer, sweetening agent, tablet and capsule diluent, 
therapeutic agent, tonicity agent. 
Applications in Pharmaceutical Formulation or Technology - Mannitol is widely used in 
Pharmaceutical formulations and food products. In pharmaceutical preparations it is primarily 
used as a diluent (10–90% w/w) in tablet formulations, where it is of particular value since it 
is not hygroscopic and may thus be used with moisture-sensitive active ingredients. Mannitol 
may be used in direct-compression tablet applications, for which the granular and spray-dried 
forms are available, or in wet granulations. Granulations containing mannitol have the 
advantage of being dried easily. Specific tablet applications include antacid preparations, 
glyceryl trinitrate tablets, and vitamin preparations. Mannitol is commonly used as an 
excipient in the manufacture of chewable tablet formulations because of its negative heat of 
solution, sweetness, and ‘mouth feel’. In lyophilized preparations, mannitol (20–90% w/w) 
has been included as a carrier to produce a stiff, homogeneous cake that improves the 
appearance of the lyophilized plug in a vial. A pyrogen-free form is available specifically for 
this use. Mannitol has also been used to prevent thickening in aqueous antacid suspensions of 
aluminium hydroxide (<7% w/v). It has been suggested as a plasticizer in soft-gelatin 
capsules, as a component of sustained-release tablet formulations, and as a carrier in dry 
powder inhalers. It is also used as diluents in rapidly dispersing oral dosage forms. It is used 
in food applications as a bulking agent. Therapeutically, mannitol administered parenterally is 
used as an osmotic diuretic, as a diagnostic agent for kidney function, as an adjunct in the 
treatment of acute renal failure, and as an agent to reduce intracranial pressure, treat cerebral 
edema, and reduce intraocular pressure. Given orally, mannitol is not absorbed significantly 
from the gastrointestinal tract, but in large doses it can cause osmotic diarrhea. 
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Description - Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is 
isomeric with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or free 
flowing granules. It has a sweet taste, approximately as sweet as glucose and half as sweet as 
sucrose, and imparts a cooling sensation in the mouth. Microscopically, it appears as 
orthorhombic needles when crystallized from alcohol. Mannitol shows polymorphism. 
Solubility of mannitol - 
Solvent                               Solubility at 20C 
Alkalis                                 Soluble 
Ethanol (95%)                    1 in 83 
Ether                                  Practically insoluble 
Glycerine                              1 in 18 
Propan-2-ol                        1 in 100 
Water                                 1 in 5.5 
Stability and Storage Conditions - Mannitol is stable in the dry state and in aqueous solutions. 
Solutions may be sterilized by filtration or by autoclaving and if necessary may be autoclaved 
repeatedly with no adverse physical or chemical effects. In solution, mannitol is not attacked 
by cold, dilute acids or alkalis, nor by atmospheric oxygen in the absence of catalysts. 
Mannitol does not undergo Maillard reactions. The bulk material should be stored in a well-
closed container in a cool, dry place. 
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4. DICALCIUM PHOSPHATE (DCP). 
Nonproprietary names -      BP: Calcium hydrogen phosphate, JP: Dibasic calcium phosphate, 
PhEur: Calcii hydrogenophosphas dihydricus and USP: Dibasic calcium phosphate. 
Synonyms - Calcium hydrogen orthophosphate dihydrate; calcium monohydrogen phosphate 
dihydrate; Di-Cafos; dicalcium orthophosphate; DI-TAB; E341; Emcompress; phosphoric 
acid calcium salt (1 : 1) dihydrate; secondary calcium phosphate. 
Chemical name - Dibasic calcium phosphate dihydrate. 
Empirical Formula and Molecular Weight - CaHPO4_2H2O   and 172.09. 
Functional Category - Tablet and capsule diluents. 
Applications in Pharmaceutical Formulation or Technology - Dibasic calcium phosphate 
dihydrate is widely used in tablet formulations both as an excipient and as a source of calcium 
and phosphorus in nutritional supplements. It is one of the more widely used materials, 
particularly in the nutritional/ health food sectors. It is also used in pharmaceutical products 
because of its compaction properties, and the good flow properties of the coarse-grade 
material. Dibasic calcium phosphate dihydrate is abrasive and a lubricant is required for 
tableting, for example about 1% w/w of magnesium stearate or about 1% w/w of sodium 
stearyl fumarate is commonly used.  
Typical Properties -  Acidity/alkalinity: pH = 7.4 (20% slurry of DI-TAB). 
Angle of repose: 28.38 for Emcompress. 
Density (bulk):     0.915 gm/cc. 
Density (tapped):  1.17 gm/cc. 
Density (true):   2.389 gm/cm3. 
Melting point:   dehydrates below 100°C. 
Solubility -Practically insoluble in ethanol, ether, and water. Soluble in dilute acids. 
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Stability and Storage Conditions - Dibasic calcium phosphate dihydrate is a non hygroscopic, 
relatively stable material. However, under certain conditions the dihydrate can lose water of 
crystallization. This has implications for both storage of the bulk material and coating and 
packaging of tablets containing dibasic calcium phosphate dihydrate. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
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5. MAGNESIUM STEARATE. 
Non-proprietary names - BP: Magnesium stearate, JP: Magnesium stearate, PhEur: Magnesii 
stearas. 
Synonyms - Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
Chemical Name - Octadecanoic acid magnesium salt. 
Empirical Formula and Molecular Weight - C36H70MgO4 and 591.34. 
Description - The USPNF 23 describes magnesium stearate as a compound of magnesium 
with a mixture of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005 describes 
magnesium stearate as a mixture of magnesium salts of different fatty acids consisting mainly 
of stearic acid and palmitic acid and in minor proportions other fatty acids.  
Structural Formula - [CH3 (CH2)16COO]2Mg. 
Functional Category - Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology - Magnesium stearate is widely 
used in cosmetics, foods and pharmaceutical formulations. It is primarily used as a lubricant 
in capsule and tablet manufacture at concentrations between 0.25 and 5.0% w/w. It is also 
used in barrier creams. Description magnesium stearate is a very fine, light white, precipitated 
or milled, impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
Crystalline forms - high-purity magnesium stearate has been isolated as a trihydrate, a 
dihydrate and an anhydrate. 
Density (bulk):      0.159 gm/cm3. 
Density (tapped):  0.286 gm/cm3. 
Density (true):      1.092 gm/cm3. 
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Flash point: 250°C. 
Flow ability:  poorly flowing, cohesive powder. 
Melting range: 117–150°C (Commercial samples), 
126–130C  (High purity magnesium stearate). 
Solubility - Practically insoluble in ethanol, ethanol (95%), ether and water. Slightly soluble 
in warm benzene and warm ethanol (95%).  
Stability and Storage Conditions - Magnesium stearate is stable and should be stored in a well 
closed container in a cool and dry place. 
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6. ISOPROPYL ALCOHOL. 
Non-proprietary names -  BP: Isopropyl alcohol, JP: Isopropanol, PhEur: Isopropyl 
alcohol, USP: Isopropyl alcohol. 
Synonyms -Alcohol isopropylicus, dimethyl carbinol, IPA, isopropanol, petrohol, 2-propanol, 
sec-propyl alcohol and rubbing alcohol. 
 Empirical Formula and Molecular Weight - C3H8O and 60.1.  
 Functional Category - Disinfectant and solvent. 
Applications in Pharmaceutical Formulation or Technology -Isopropyl alcohol (propan-2-ol) 
is used in cosmetics and pharmaceutical formulations, primarily as a solvent in topical 
formulations. It is not recommended for oral use owing to its toxicity; although it is used in 
lotions, the marked degreasing properties of isopropyl alcohol may limit its usefulness in 
preparations used repeatedly. Isopropyl alcohol is also used as a solvent both for tablet film-
coating and for tablet granulation,(2) where the isopropyl alcohol is subsequently removed by 
evaporation. It has also been shown to significantly increase the skin permeability of 
nimesulide from carbomer. Isopropyl alcohol has some antimicrobial activity and a 70% v/v 
aqueous solution is used as a topical disinfectant. Therapeutically, isopropyl alcohol has been 
investigated for the treatment of postoperative nausea or vomiting. 
Typical Properties - Antimicrobial activity Isopropyl alcohol is bactericidal; at concentrations 
greater than 70% v/v it is a more effective antibacterial preservative than ethanol (95%). The 
bactericidal effect of aqueous solutions increases steadily as the concentration approaches 
100% v/v. Isopropyl alcohol is ineffective against bacterial spores. 
Autoignition temperature is 425°C. Boiling point 82.4°C. Dielectric constant D20 = 18.62. 
Explosive limits 2.5–12.0% v/v in air. Flammability Flammable: Flash point 11.7°C (closed 
cup), 138°C (open cup). The water azeotrope has a flash point of 16°C. 
Melting point - 88.5°C. Moisture content is 0.1–13% w/w for commercial grades (13% w/w 
corresponds to the water azeotrope). Solubility: Miscible with benzene, chloroform, ethanol 
(95%), ether, glycerin and water. Soluble in acetone and insoluble in salt. 
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7. POVIDONE. 
 
Synonyms - Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene], polyvidone; 
polyvinyl pyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer. 
Chemical name - 1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical formula - (C6H9NO) n    
Molecular Weight - 2500–3000000. 
Functional Category - Disintegrant; dissolution aid; suspending agent; tablet binder 
Description - Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidone with K-values equal to or lower than 30 are 
manufactured by Spray-drying and occur as spheres. Povidone K-90 and higher K-value 
povidones are manufactured by drum drying and occur as plates.                           
 Solubility - Freely soluble in acids, chloroform, ethanol (95%),ketones, methanol, and water; 
practically insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration of a 
solution is limited only by the viscosity of the resulting solution, which is a function of the 
K-value.                                  
Stability and storage - Povidone is stable. However it is a hygroscopic material. It should be 
stored in airtight container cool and dry place. 
Applications - In tableting, povidone solutions are used as binders in wet granulation 
processes. Povidone is used as a solubilizer in oral and parenteral formulations and has been 
shown to enhance dissolution of poorly soluble drugs from solid-dosage forms. Povidone 
solutions may also be used as coating agents as a carrier for the drugs (10-25%); as binder 
(0.5- 5%). Suspending and viscosity builder up to 5%. 
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 6. EXPERIMENTAL SECTION 
 
PREPARATION OF pH 7.2 PHOSPHATE BUFFER: 
            Place 50ml of 0.2M potassium dihydrogen phosphate in 200ml of volumetric flask and 
specified volume 0.2M  NaoH (34.7ml) make up to volume. 
0.2M Potassium dihydrogen phosphate: 
        Dissolve 27,218gm of potassium dihydrogen phosphate in water and dilute with water to 
1000ml. 
0.2M  Sodiumhydroxide (NaoH ): 
         Dissolve NaoH in water to produce a 40 to 60 percent w/v solution and allow to 
stand.Taking precautions to avoid the absorption of CO2 siphon off the clear supernatant 
liquid and dilute with carbondioxide free water a sutible volume of the liquid containing 8gm 
of NaoH IN 1000ml. 
PREPARATION OF STANDARD CURVE FOR IBUPROFEN: 
          Accurately 100 mg of pure drug was weighed and it taken in 100 ml volumetric flask. 
The drug was dissolved in 100ml of phosphate buffer pH-7.2 in a 100 ml volumetric flask. 
Now the solution was shaked till the drug dissolved completely. Then the primary solution 
was kept for 30 min and the solution was then filtered. From this primary solution, 10 ml of 
solution was taken in another 100 ml volumetric flask and the solution was then diluted with 
phosphate buffer pH-7.2 and the volume was adjusted up to 100 ml. From this stock solution, 
1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 ml were taken in a 10 ml volumetric flask. These solutions were 
diluted with phosphate buffer pH-7.2 up to 10 ml. Absorbance studies of all the solutions 
were carried out by using UV-Visible spectrophotometer at λmax 221 nm is given in Table 11. 
The regression equation obtained from the graph plotted by taking absorbance vs 
concentration was y = 0.0045x - 0.0001, with regression co-efficient value is 1.00, as 
represented in Fig 4. 
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Table 4. Standard curve of ibuprofen in phosphate buffer pH 7.2. 
Sl. No. Concentration (µg/ml) Absorbance 
1 10 0.045 
2 20 0.09 
3 30 0.136 
4 40 0.181 
5 50 0.226 
6 60 0.271 
 
 
Fig 4. Calibration curve of ibuprofen pure drug in phosphate buffer pH 7.2. 
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METHODOLOGY. 
 Preformulation studies16,17. 
Preformulation activities range from supporting discovery’s identification of new 
active agents to characterizing physical properties necessary for the design of dosage form. 
Critical information provided during preformulation can enhance the rapid and successful 
introduction of new therapeutics entities for humans. Preformulation testing is an 
investigation of physical and chemical properties of a drug substance alone and when 
combined with excipients. It is the first step in the rational development of dosage form. 
The overall objective of preformulation testing is to generate information useful in 
developing the formulation which is stable and bioavailability. Further the use of 
preformulation parameters maximizes the chances in formulating an acceptable, safe, 
efficacious and stable product. For any drug substance to formulate into a dosage form, it is 
necessary to study the physicochemical properties of the bulk drug like physical appearance, 
solubility, bulk density, tapped density, compressibility, molecular weight, sieve analysis. 
1. PHYSICAL APPEARANCE:  
A small quantity of ibuprofen was taken in butter paper and viewed in well 
illuminated place. Finally the colour, odour and texture were observed.  
2. SOLUBILITY21,22: 
A semi-quantitative determination of the solubility was made by adding solvent in 
small incremental amount to a test tube containing fixed quantity of solute or vice versa. After 
each addition, the system vigorously shaken and examined visually for any undissolved solute 
particles. The solubility was expressed in terms of ratio of solute and solvent. 
3. BULK DENSITY21,22: 
 A bulk density is defined as the ratio of mass of the drug and its bulk volume. Exactly 
50 gm of drug were weighed on digital balance and transferred into a 100 ml measuring 
cylinder. The volume occupied by the drug was recorded as the bulk volume. This is the bulk 
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volume and the bulk density was calculated. It is expressed in gm/cc and is given by, Db 
(gm/cc) =
Vb
M
, Where, M is the mass of drug in gm and Vb is the bulk volume of the drug. 
4. TAPPED DENSITY21,22: 
              Tapped densities of drug are defined as the ratio of mass of the drug and its tapped 
volume.  
 Exactly 50 gm of pure drug were weighed on digital balance and transferred into a 100 
ml measuring cylinder. The cylinder was tapped on the wooden platform until the volume 
occupied by the drug remained constant. This is the tapped volume and the tapped density 
was calculated. It is expressed in g/cc and is given by, Tb (gm/cc) =
Vt
M
, Where, M is the 
mass of drug in gm and Vt is the bulk volume of the drug. 
                 Tapped density = Wt. of sample in gm / Tapped volume 
 5. COMPRESSIBILITY INDEX21,22: 
             It indicates powder flow properties. It is expressed in percentage by comparing the 
bulk density and tapped density. A useful empirical guide is given by Carr’s compressibility3. 
                           Carr’s Index (%) = 100
density Tapped
densityBulk  -density  Tapped
×  
Table 5. Carr’s Index and flow property relationship. 
Sl. No. Carr’s  Index Properties 
1 5-12 Free flowing 
2 12-16 Good 
3 18-21 Fair 
4 23-35 Poor 
5 33-38 Very poor 
6 >40 Extremely poor 
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6. HAUSNERS RATIO21,22: 
Hausner’s Ratio provides an indication of the degree of densification which could 
result from vibration of the feed hopper. It is measured by the ratio of tapped density to the 
bulk density. Hausner’s Ratio = 
densityBulk 
density Tapped
  
 
Table 6. Hausner’s ratio and flow property relationship. 
Sl. No. Hausner’s Ratio Property 
1 <1.25 Better flow ability 
2 >1.25 Poor flow ability 
 
 
7. ANGLE OF REPOSE21,22: 
   Angle of repose was determined by fixed funnel method. Funnel with the end of the 
stem cut perpendicular to the axis of symmetry was secured with its tip at a given height (H) 
above a graph paper placed on a flat horizontal surface. About 50 gm of the drug were placed 
in a plugged glass funnel which had a distance of 10 cm from the surface. The drug was then 
allowed to flow through the 8 mm funnel orifice by removing the cotton plug from the funnel 
orifice. The height of the heap (h) formed as well as the radius of the heap (r) was noted. The 
angle of repose (θ) was calculated as θ = tan-1 h/r. 
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Table 7. Angle of repose and flow property relationship. 
Angle of repose (0) Powder flow 
< 26 Excellent 
26 – 30 Good 
30 – 40 Passable 
> 40 Very poor 
 
Drug excipient compatibility studies16: 
The compatibility studies are carried out to study the possible interactions between 
ibuprofen and inactive ingredients. Physical mixtures of ibuprofen and excipients in different 
ratio are prepared and kept for stability at 400C±20/75%±5% RH for one month. Samples are 
subjected to physical (Colour, appearance) and chemical testing (Assay of ibuprofen and 
impurities). 
              The compatibility studies are carried out by taking a mixture of drug and excipients 
at the ratio in which they are expected to be present in the innovator product. A part of 
mixture can be exposed to different storage conditions like 400C±20/75%±5%  RH and control 
samples are to be kept at 2-8oC. They are tested with respect to their physical and chemical 
aspects. 
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Table 8. Composition of Ibuprofen controlled release tablets. 
Ingredients              (mg) Formulations 
F1 F2 F3 F4 F5 F6 
Ibuprofen 600 600 600 600 600 600 
Stearic acid 100 100 - - - - 
Glyceryl behanate - - 100 100 - - 
Xanthan gum - - - - 250 250 
Mannitol 265 - 265 - 115 65 
DCP - 265 - 265 - 50 
Povidone K30 25 25 25 25 25 25 
IPA Qs Qs Qs Qs Qs Qs 
Magnesium Stearate 10 10 10 10 10 10 
Total tablet weight 1000 1000 1000 1000 1000 1000 
Qs Denotes quantity sufficient. 
 
 Granulation and compression for manufacturing of ibuprofen control release tablets: 
Here the drug is homogenously dispersed throughout a rate controlling medium. 
Hydrophobic and hydrophilic matrices are used to control the release of the drug having 
different solubility properties. The drug Ibuprofen was selected for the formulation of matrix 
tablets. Different polymers like stearic acid, glyceryl behanate, xanthan gum with other 
Chapter 6. Experimental section 
                         DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLET Page 52 
excipients like mannitol, DCP & lubricants like magnesium stearate were used in all the 
formulations. All the formulations were formulated by wet granulation method. The 
procedure employed for each formulation is given below. 
Accurately weighed quantities of ingredients along with drug mentioned in Table 7 
were passed through sieve No. 60. All the ingredients, except lubricant (Magnesium stearate) 
and binder povidone K30, were manually blended homogeneously in a mortar by way of 
geometric dilution. The mixture was moistened with solution of 10% (W/V) povidone K30, 
isopropyl alcohol, granulated and passed  through sieve No. 16 and dried in a hot air oven at 
60 0C for sufficient time (3 to 4 h) so that the moisture content of the granules reached 2–4%. 
The dried granules were passed through sieve No. 44 and blended with magnesium stearate. 
The homogeneous blend was then compressed into tablets using capsule shaped punches of 
size 14 mm. 
 CHARACTERIZATION OF GRANULES: 
1. BULK DENSITY. 
 Exactly 50 gm of granules were weighed on digital balance and transferred into a 100 
ml measuring cylinder. The volume occupied by the granules was recorded as the bulk 
volume. This is the bulk volume and the bulk density was calculated. It is expressed in g/cc 
and is given by, Db (gm/cc) =
Vb
M
, Where, M is the mass of drug in gm and Vb is the bulk 
volume of the granules. 
2. TAPPED DENSITY. 
              Exactly 50 gm of granules were weighed on digital balance and transferred into a 100 
ml measuring cylinder. The cylinder was tapped on the wooden platform until the volume 
occupied by the drug remained constant. This is the tapped volume and the tapped density 
was calculated. It is expressed in g/cc and is given by, Tb (g/cc) =
Vt
M
, Where, M is the mass 
of drug in gm and Vt is the bulk volume of the drug. 
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 3. COMPRESSIBILITY INDEX. 
It is expressed in percentage by comparing the bulk density and tapped density. A 
useful empirical guide is given by Carr’s compressibility. 
Carr’s Index (%) = 100
density Tapped
densityBulk  -density  Tapped
×   
4. HAUSNERS RATIO. 
It is measured by the ratio of tapped density to the bulk density.  
Hausner’s Ratio = 
densityBulk 
density Tapped
  
5. ANGLE OF REPOSE. 
   Angle of repose was determined by fixed funnel method. Funnel with the end of the 
stem cut perpendicular to the axis of symmetry was secured with its tip at a given height (H) 
above a graph paper placed on a flat horizontal surface. About 50 gm of the drug were placed 
in a plugged glass funnel which had a distance of 10 cm from the surface. The drug was then 
allowed to flow through the 8 mm funnel orifice by removing the cotton plug from the funnel 
orifice. The height of the heap (h) formed as well as the radius of the heap (r) was noted33,34. 
The angle of repose (θ) was calculated as θ = tan-1 h/r. 
 Evaluation of tablets: 
1. THICKNESS. 
  The thickness of tablets will be the only dimensional variable related to the process. 
About 10 tablets were measured for their thickness and diameter with a slide calliper, 
thickness Gauge. Average thickness and diameter were calculated. 
2. WEIGHT VARIATION. 
  The USP weight variation test was done by weighing 20 tablets individually, the 
average weight was then calculated and comparing the individual tablet weights to the 
average weight. The tablets met the USP tests that were not more than 2 tablets were outside 
the percentage limit and no tablets differed by more than 2 times the percentage limit. 
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3. CONTENT UNIFORMITY. 
          About 20 tablets were selected randomly from each formulation, weighed. The weighed 
tablets were powdered. The powder equivalent to 100 mg of diclofenac sodium was 
accurately weighed and dissolved in phosphate buffer pH 7.2. After suitable dilution, the 
solution was analyzed for drug content by using UV-Visible spectrophotometer at 221 nm. 
4. FRIABILITY. 
             The friability of tablets was determined by Roche Friabillator. About 20 tablets were 
taken and weighed. After weighing, the tablets were placed in the Roche Friabillator and 
subjected to the combined effects of abrasion and shock by utilizing a plastic chamber that 
revolves at 25 rpm for min dropping the from a distance of six inches with each revolution. 
After operation the tablets were de-dusted and reweighed. 
Friability is determined by F=100(W0-Wt/W0), Where,   Wo = weight of tablets before 
friability test, Wt = weight of tablets after friability test.  
5. HARDNESS TEST:  
Hardness of the tablets was determined by Monsanto Hardness Tester and the 
hardness should be found within the range of 3.5-5.5 Kg/cm². 
Invitro dissolution studies24: 
 The dissolution was carried out for different experimental trials and also for the 
innovator. The various results obtained were tabulated. Dissolution studies are carried out in 
the following media 
Dissolution parameters: 
Medium : 7.2 pH phosphate buffer. 
Quantity : 900 ml. 
Apparatus : USP apparatus II ( paddle).  
RPM : 50 rpm 
Temperature : 37ºC ± 0.50c 
Time intervals : 1hr,2hr,and up to24 hrs. 
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Calculation: 
Factor: -     1    x    W1   x     5  x   500 x  P1   x   100 
       As          100       5     L.C      100 
 
             W1 =   weight of working Standard 
L.C= Label claim in mg 
P1 =    % potency of working Standard  
As=   Absorbance of standard 
 
STABILITY STUDY25. 
To asses the stability against temperature and light, optimized tablet formulation of 
ibuprofen were stored at storage condition of 40°C /75% RH for three months and various 
parameters like avg. weight, hardness, thickness, friability and drug content was determined 
periodically with 1 month interval. The study was continued up to three months. 
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7. RESULTS AND DISCUSSION 
In process of pursuing the objective of control release drug delivery system; this 
research was aimed towards the formulation development of control release tablet for oral use 
to provide sustained release of ibuprofen for prolong period of time. 
1. PREFORMULATION STUDIES. 
The ibuprofen was white in colour, odourless, bitter in taste and powdery in 
appearance.  
 
 Table 9.Solubility values of crude drug in different solvent 
S.No         Solvent      Solubility(mg/ml) 
1          Water            0.01 
2         Acetone             0.12      
3         Ethanol             0.25 
4      Chloroform             0.18 
5 phosphate buffer pH  7.2             0.9 
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 The bulk density of the powder was found to be 1.123 gm/cc. The tapped density of the 
powder was found to be 1.273 gm/cc. The Carr’s Index was found to be 11.783 indicating 
good flow properties. The Hausner’s ratio was found to be 1.133 and the value was indicating 
better flow properties.The angle of repose was obtained as 27.22°, indicating good flow of 
powder drug. 
 
 Table 10.Preformulation studies of Ibuprofen 
S.No Parameter Result 
1 Bulk density 1.123gm/cc 
2 Tapped density 1.273gm/cc 
3 Carr’s index 11.783% 
4 Haussner’s ratio 1.133 
5 Angle of repose 27.22° 
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2 Drug excipient compatibility studies. 
 
Table 11. Drug–excipients compatibility studies. 
Sl. No. Excipients Ratio Description Compatibility 
status 
Initial Final 
1 Ibuprofen  
- 
White to off white 
powder 
White to off white 
powder 
Compatible 
2 
 
API – DCP 1:20 Off white coloured 
powder 
Off white coloured 
powder 
compatible 
3 API – Mannitol 1:20 
 
Off white colored 
powder 
Off white coloured 
powder 
compatible 
4 API – Glyceryl 
dibehenate 
1:5 Off white coloured 
powder 
Off white coloured 
powder 
compatible 
5 API – Magnesium 
stearate 
1:0.25 Off white colored 
powder 
Off white colored 
powder 
compatible 
6 API – Stearic acid  1:5 Off white colored 
powder 
Off white colored 
powder 
Compatible 
7 API – Xanthan gum 1:10 Off white colored 
powder 
Off white colored 
powder 
Compatible 
    
 
 
The result of drug excipient compatibility study is represented in Table 11. It  could 
be concluded from the result of drug excipient compatibility study, there no such physical 
interaction are there between drug and excipient explaining, drug and excipient were 
compatible with each other for designing of control release tablet of ibuprofen. 
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3 Characterization of granules. 
 
Table 12. Flow properties data of various granule formulations containing ibuprofen. 
 
The result of flow properties of prepared granules of various formulations of 
ibuprofen is given in Table 12. Flow properties of the granules, resistance to particle 
movement can be judged from the bulk density, tapped density, compressibility index, 
Hausner’s ratio and angle of repose. This measurement gives qualitative and quantitative 
assessment of internal cohesive and frictional force under low levels of external loading as 
might be applied in mixing and tabletting. The bulk density was found within the range of 
0.42 to 0.56 g/cc. The tapped density was found within the range of 0.54 to 0.67 g/cc. Using 
the density data, Hausner’s ratio and Carr’s index was calculated. The Hausner’s ratio was 
found within the ranges of 1.185 to 1.250 which indicates better flowability. The Carr’s index 
was found within the ranges of 15.625 to 20.001, explaining good flow properties. The angle 
of repose was found using fixed funnel method, which is within the ranges of 26.67 to 29.12, 
indicating good flow properties.  
Formulation 
Bulk   
density 
(gm/cc) 
Tapped    
density    
(gm/cc) 
Compressibility 
index (%) 
Hausner’s 
ratio 
Angle 
of 
repose 
(°) 
Flow 
comment 
F1 0.54 0.64 15.625 1.185 26.67 Good  
F2 0.52 0.65 20.001 1.250 25.87 Good 
F3 0.56 0.67 16.417 1.196 27.08 Good 
F4 0.45 0.54 16.667 1.200 28.98 Good 
F5 0.46 0.57 19.298 1.239 26.66 Good 
F6 0.49 0.59 16.949 1.204 29.12 Good 
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4 Evaluation data of control release tablet of ibuprofen. 
Table 13. Physicochemical properties of prepared tablet formulations. 
Formulations Avg. wt.      
(mg) 
Thickness   
(mm) 
Hardness 
Kg/cm2 
Drug content 
(%) 
Friability   
(%) 
F1 980 2.4 4 98.4 0.013 
F2 978 2.6 3.5 99.5 0.025 
F3 980 2.8 5 97.2 0.023 
F4 995 2.5 4 98.9 0.019 
F5 975 2.3 4.5 98.2 0.022 
F6 979 2.7 4 98.8 0.018 
 
The tablets of various formulations were subjected to various evaluation tests, such as 
thickness, weight variation, friability, hardness, and drug release rate by dissolution studies 
according to the procedure specified in the I.P. All formulations are found to be satisfactory. 
 The physical examination of tablets showed that the tablets were circular or round in 
shape. The studies also indicated that there were no cracks on the tablets. The data indicates 
that all the formulations were good.  
The thickness of each batch tablets of all formulations was determined and the results 
presented in Table 13. Thickness of tablets was found to be almost uniform in all the six 
formulations. They were found to be in the ranges of 2.3 to 2.8 mm.  
The weight variation test (%) was conducted for each batch formulations (n=10) as 
per I.P and the results are shown in the Table 13. All the tablets passed weight variation test 
as the % weight variation, which was within the Pharmacopoeial limits of ± 5% of the 
weight. The average weight of all tablet formulations was within the ranges of 975 to 995 mg. 
The weights of all the tablets were found to be almost uniform. 
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The adequate tablet hardness is the necessary requisite for consumer acceptance and 
handling. The measured hardness of tablets of each batch of all formulations was ranged 
between 3.5 to 5 Kg/cm2, which is falling within the hardness specification as per I.P.  
The friability test for tablet formulations was done as per the standard procedure of 
I.P. The results of friability test were tabulated in Table 13. The friability of tablets within the 
ranges between 0.013 to 0.025, which are generally considered and acceptable as per I.P. The 
data indicates that the percentage friability was less than 1% in all the formulations ensuring 
no physical damage will be take place during handling and shipping of tablets.  
The drug content of each formulation was evaluated as per the standard protocol and 
the results are shown in Table 13. The results indicate that the percentage of drug content was 
within the ranges of 97.2 to 99.5 % of paracetamol which was within the acceptable limits as 
per the I.P 
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Invitro Dissolution studies: 
 
Table 14. In vitro drug release profile of various control release tablet formulations. 
Sl. No. Time                  
( h) 
Cumulative percentage of drug Release 
F1 F2 F3 F4 F5 F6 
1 1 25 19 23 21 30 26 
2 2 30 25 31 28 42 38 
3 4 42 31 41 35 54 45 
4 5 50 39 53 42 65 54 
5 6 55 43 60 48 75 62 
6 8 62 49 70 59 89 76 
7 10 70 57 82 67 91 84 
8 12 77 63 89 75 93 91 
9 16 86 68 94 82 97 95 
10 24 96 74 98 91 99 99 
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Fig 5. In vitro drug release profile of various control release tablet formulations. 
% C D R: Cumulative percentage of drug Release 
 
In vitro drug release profiles of prepared control release tablet of ibuprofen were 
shown in Table 14. The release of drug from the tablet exhibited a sustained pattern, in 
controlled manner over extended period of time. The release patterns of all the formulations 
were represented in Fig 5. Most of the formulations release drug in a constant manner except 
formulation F3 and F5. From the cumulative drug release data, the control release tablet 
formulation F2 was found to release the drug only 74 % even after 24 h, thus concluded to 
have sustained release of drug in constant manner for longer period of time when compared 
to other tablet formulations. 
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Stability studies: 
Table 15. Stability data -parameters of optimized ibuprofen tablet formulation F2 for 
three months at 40°C /75% RH. 
Sl. No Parameters Initial 1st month 2nd month 3rd month 
1 Avg. weight (mg) 978 978 977 977 
2  Hardness (kg/ cm2) 3.5 3.5 3.5 3.5 
3 Thickness (mm) 2.6 2.6 2.6 2.6 
4     Friability (%) 0.025 0.025 0.025 0.025 
5 Drug content (%) 99.5 99.45 99.25 99.07 
 
 
Stability studies were carried out for optimized formulation (F2) for three months at 
40°C /75% RH. The data of stability study is given in Table 15. No significant variation was 
found in hardness of the tablet, thickness, drug content and friability after three months in 
above storage condition, assuring optimized tablet will be stable during the storage condition. 
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8. CONCLUSION 
Oral controlled drug delivery system is perhaps the relatively very advanced, newer 
area of research of its kind. This state-of-the-art formulation development offers several 
benefits like increased therapeutic efficacy, decreased side effects etc. Biocompatible and 
biodegradable xanthum gum, glyceryl behanate and stearic acid were experimented with 
ibuprofen which has served as a model drug for development of controlled release oral tablet.  
Oral control tablet of ibuprofen with very good physical characteristics were 
developed. The method of preparation of tablet of ibuprofen was found to be simple and 
reproducible. The sustained release of ibuprofen from the development oral tablet will help to 
improve the therapeutic efficacy and patient compliance by reducing the dose and frequency 
of dosing of ibuprofen perhaps as in vitro dissolution study suggested only 74 % (F2) release 
of drug over 24 h period. This work shows that stearic acid loaded tablet of ibuprofen could 
be oral control drug delivery system for ibuprofen for prolonged release. Thus concluding 
control release tablet of ibuprofen could improve upon physicochemical and biological 
properties of ibuprofen.  
 
Chapter . References 
              DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLETS  
BIBLIOGRAPHY 
1. Y.W. Chien, Novel drug delivery systems. In: Drug and Pharmaceutical Sciences, 2nd 
ed., Marcel Dekker Inc.  New York, 1992:1-139. 
2. D.M. Brahmankar, S.B. Jaiswal, Biopharmaceutics and pharmacokinetics, A Treatise, 
2nd ed., Vallabh prakashan, New Delhi, 2009:345-47. 
3. M. E. Aulton, Process Granulation. In: Pharmaceutics-The Design and Manufacture 
of Medicines. Churchil Livingstone, London New York, 2007: 176-89. 
4. S.P. Vyas, R.K. Khar, Control Drug Delivery: Concepts and advance, Vallabh 
Prakashan, New Delhi, 1st ed., 2002: 292-93. 
5. L. Lachman, H.A. Lieberman and J.L. Kanig, The theory and practice of Industrial  
Pharmacy, 3rd  ed., Vaerghese Publishing House, Mumbai, 1987: 430−56.  
6. R. Patel, Ibuprofen, a weekly acidic, non-steroidal anti inflammatory drug having 
high permeability through stomach, Int.l J. Res. Pharm. Sci., 2010, 1, 57-64. 
7. S. Chandran, Controlled release preparations have been reported to reduce the gastro 
irritant and ulcerogenic effects of non steroidal anti-inflammatory drugs, Indian J. 
Pharm. Sci., 2008, 70 (2 ): 596-602. 
8. G.S. Sonar, A bilayer and floating-bioadhesive drug delivery system exhibiting a 
unique combination of floatation and bioadhesion to prolong residence in the stomach 
using Ibuprofen as a model drug, Indian J. Pharm. Educ. Res., 2007, 37(3): 329-32. 
9. S.S. Krishna, Formulationn of control the release of ibuprofen using mucoadhesive 
tablet, Asian J. Pharm. Sci., 2006, 1 (7): 54-9. 
10. M.H. Shoaib, Sustained release matrix tablet of ibuprofen using hydroxypropyl 
methylcellulose (HPMC) as release controlling factor, Development of 
Pharmaceutical University, Karachi, Pakistan, 2005, 19 (2): 119-24. 
Chapter . References 
              DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLETS  
11. P. Thapa, formulation of control release oral delivery system and to investigate the 
influence of different diluents, Kathmandu University J. Sci. Engg. and Tech., 
2005,1(2):45-52. 
12. B. Arika, The irritation effects of ibuprofen, a widely used non-steroidal anti-
inflammatory drug (NSAID), J. of Microencapsulation, 2005, 22: 153-65. 
13.  S. Turner, The release characteristics of a novel 600mg controlled release tablet 
formulation of ibuprofen using in vitro dissolution studies and in vivo human 
pharmacokinetic studies, Scolar Pharma Lnc., Schools of Pharmacy, 2005.  
14. R. Canaparo, A specific method for the simultaneous determination of S-(+) 
Ibuprofen and R-(-) Ibuprofen enantiomers in human plasma, Department of 
Electronics Polytechnic of Torino, Torino, Italy, 2000: 219-116. 
15. M. Rafece., Need For controlled release formulations of ibuprofen tablet, Drug Dev. 
and Ind. Pharmacy, 1999, 21: 1193-202. 
16. Monographs and appendix, In: Indian Pharmacopeia, Govt. of India, Ministry of 
Health and Family Welfare,  Indian Pharmacopeia Commission, Gaziabad, 2007; Vol 
– 1, 2, 3: 1514 – 515. 
17. British Pharmacopeia, The Dept. of Health Society, Service and Public Safety, 2005, 
Vol (3):  2703. 
18. K.D Tripathy, Paracetamol, In: essentials of medicinal Pharmacology, 2008; 6th 
ed:198-99. 
19. J.R. Robinson, X Yang, Encyclopaedia of Pharmaceutical Technology, Marcel 
Dekkar Inc., New York, Vol. (18): 1-27. 
20. R.C. Rowe, P.J. Sheskey, M.E. Quinn, Hand Book of Pharmaceutical Excipients, 6th 
ed., : 364 - 728. 
 
Chapter . References 
              DESIGN AND EVALUATION OF CONTROLLED RELEASE FORMULATIONS OF IBUPROFEN TABLETS  
 
21. C.V.S subrahmanyam, J. T. Setty, Laboratory manual of physical pharmaceutics, 1st 
ed., 2002, Vallabh Prakashan, Delhi: 102-108. 
22. H.N. More, A.A. Hajare, practical physical pharmacy, 1st ed., Career Publication, 
Nasik, Maharashtra, 2007. 
23. N. Grattarda, M. Perninb, B. Martyb, G. Roudauta and D.Champion, Study of release 
kinetics of small and high molecular weight substances dispersed into spray-dried 
ethyl cellulose microspheres, J. Control Release, 2002, 84: 125-135. 
24. T. Higuchi, Mechanism of rate of sustained-action medication, J. Pharm. Sci.                
1963, 52(11): 1145-149. 
25. JT. Carstensen, Drug Stability, Principles & Practices, Marcel Dekker, New York, 
1989.vol(1):17-58. 
  
 
 
